Loading...
XNYSDHR
Market cap165bUSD
Dec 20, Last price  
228.55USD
1D
1.06%
1Q
-16.17%
Jan 2017
193.62%
Name

Danaher Corp

Chart & Performance

D1W1MN
XNYS:DHR chart
P/E
34.65
P/S
6.91
EPS
6.60
Div Yield, %
0.50%
Shrs. gr., 5y
0.91%
Rev. gr., 5y
3.73%
Revenues
23.89b
-24.09%
6,889,301,0007,984,704,0009,596,404,00011,025,917,00012,697,456,00011,184,938,00013,202,602,00016,090,540,00018,260,400,00019,118,000,00019,913,800,00020,563,100,00016,882,400,00018,329,700,00019,893,000,00017,911,100,00022,284,000,00029,453,000,00031,471,000,00023,890,000,000
Net income
4.76b
-33.92%
746,000,000897,800,0001,122,029,0001,369,904,0001,317,631,0001,151,704,0001,793,000,0002,172,264,0002,392,200,0002,695,000,0002,598,400,0003,357,400,0002,553,700,0002,492,100,0002,650,900,0003,008,200,0003,646,000,0006,433,000,0007,209,000,0004,764,000,000
CFO
7.16b
-15.91%
1,033,216,0001,203,801,0001,547,251,0001,645,775,0001,859,029,0001,800,834,0002,084,351,0002,626,267,0003,415,000,0003,585,300,0003,758,400,0003,801,800,0003,521,800,0003,477,800,0004,022,000,0003,951,600,0006,208,000,0008,358,000,0008,519,000,0007,164,000,000
Dividend
Sep 27, 20240.27 USD/sh
Earnings
Jan 28, 2025

Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
URL
https://www.danaher.com/
IPO date
Dec 10, 1969
Employees
79,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
23,890,000
-24.09%
31,471,000
6.85%
29,453,000
32.17%
Cost of revenue
11,359,000
14,267,000
13,243,000
Unusual Expense (Income)
NOPBT
12,531,000
17,204,000
16,210,000
NOPBT Margin
52.45%
54.67%
55.04%
Operating Taxes
823,000
1,083,000
1,251,000
Tax Rate
6.57%
6.30%
7.72%
NOPAT
11,708,000
16,121,000
14,959,000
Net income
4,764,000
-33.92%
7,209,000
12.06%
6,433,000
76.44%
Dividends
(821,000)
(818,000)
(742,000)
Dividend yield
0.48%
0.42%
0.31%
Proceeds from repurchase of equity
68,000
31,000
3,335,000
BB yield
-0.04%
-0.02%
-1.38%
Debt
Debt current
1,875,000
591,000
8,000
Long-term debt
18,795,000
20,148,000
23,264,000
Deferred revenue
249,000
235,000
213,000
Other long-term liabilities
4,814,000
6,550,000
7,699,000
Net debt
14,801,000
14,733,000
20,666,000
Cash flow
Cash from operating activities
7,164,000
8,519,000
8,358,000
CAPEX
(1,383,000)
(1,152,000)
(1,294,000)
Cash from investing activities
(7,081,000)
(2,234,000)
(12,987,000)
Cash from financing activities
(273,000)
(2,570,000)
1,295,000
FCF
10,945,000
14,795,000
13,877,000
Balance
Cash
5,864,000
5,995,000
2,586,000
Long term investments
5,000
11,000
20,000
Excess cash
4,674,500
4,432,450
1,133,350
Stockholders' equity
39,339,000
38,018,000
35,087,000
Invested Capital
73,414,500
71,428,550
73,424,650
ROIC
16.17%
22.26%
21.85%
ROCE
16.05%
22.68%
21.80%
EV
Common stock shares outstanding
743,100
737,100
736,800
Price
231.34
-12.84%
265.42
-19.33%
329.01
48.11%
Market cap
171,908,754
-12.13%
195,641,082
-19.29%
242,414,568
51.84%
EV
186,713,754
212,050,082
266,358,568
EBITDA
14,697,000
19,426,000
18,378,000
EV/EBITDA
12.70
10.92
14.49
Interest
286,000
211,000
238,000
Interest/NOPBT
2.28%
1.23%
1.47%